Cyriac Roeding

Opinion author

Cyriac Roeding is the CEO and cofounder of Earli, a Silicon Valley-based cancer therapeutics firm that creates genetic switches that only turn on in cancer cells, and reprogram them to then produce their own immuno therapies against themselves. Roeding is a serial entrepreneur with prior startups and a $250M acquisition of his prior company shopkick. He also built CBS’s mobile division. In addition, Cyriac Roeding is an investor in startups ranging from CRISPR to brain-machine interfaces to artificial intelligence, including OpenAI, and a dozen top venture capital funds. He was named a Tech Pioneer and Global Innovator by the World Economic Forum.

Microscope icon. Molecule and communication background. Connected lines with dots.

Opinion

Trump Must Make Biotech Innovation a National Priority

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.

January 14, 2026

7 min read

Cyriac Roeding